At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Inhibition of Intestinal Glucose Absorption by the Bioflavonoid Quercetin in the Obese and in Obese Type 2 Diabetics
In Brief
A Phase 2 clinical trial evaluating Quercetin and Placebo for Obesity and Diabetes. Completed, enrolled 24 participants across 1 site.
Signals
Detailed Summary
Quercetin is a compound naturally found in various foods. It may have some role in the treatment of obesity and diabetes. The purpose of this study is to investigate research volunteers with obesity or obesity with type 2 diabetes to determine whether quercetin affects the way glucose is absorbed by the body. Thirty two participants aged 19 to 65 who are considered to be medically obese or obese with type 2 diabetes will be enrolled in this study. Before the onset of treatment, they will undergo a medical history, physical exam, blood work, and urinalysis. During the study, participants will be given an oral glucose tolerance test three times; during these tests they will receive 1 or 2 grams of quercetin, or placebo. Researchers will collect blood samples and analyze the effect of the treatment on blood glucose.
Study Details
Timeline
Arms & Interventions
1 gram quercetin with 6 hour OGTT
2 gram quercetin with 6 hour OGTT
placebo with 6 hour OGTT
Interventions
1 or 2 grams of quercetin or placebo will be given while patients undergo 6-hour OGTT